A Potential Role for PARP Inhibitors in Pancreatic Cancer
Due to numerous factors, including rising rates of obesity and smoking, for example, pancreatic cancer jumped to number three, and…
Multicenter Trial Focuses on Neoadjuvant Treatment for Borderline Resectable and Locally Advanced Disease
Dr. David Ryan outlines a new trial for pre-surgical pancreatic cancer treatment combining a blood pressure drug, immunotherapy, standard care and SBRT.
Collaborative Multi-Center Immunotherapy Trial Targets CD40 and PD-1
Dr. Mark O’Hara outlines a collaborative clinical trial of two immunotherapy agents–a checkpoint inhibitor and a monoclonal antibody–plus standard chemotherapy.
Targeting Cancer Metabolism
Researchers from Tyme Technologies are focusing on cancer cell metabolism, particularly tyrosine, as a way to kill cancer cells.
Precision Medicine from the Get-Go for Pancreatic Cancer
Dr. Ben George and colleagues at the Medical College of Wisconsin are using molecular profiling to determine the best chemotherapy for a patient’s pancreatic cancer.
A Simple Blood Test for Early Detection of Eight Cancers Shows Promise
Dr. Anne Marie Lennon explains the CancerSEEK blood test, a liquid biopsy in clinical trials for early detection of eight cancers, including pancreatic.
Standard of Care Plus
Dr. Allyson Ocean explains why pancreatic cancer patients should consider clinical trials, which go beyond standard of care.
More Research Needed for Pancreatic Cancer Immunotherapy
Dr. Luis Diaz provides a status check for immunotherapy treatments for pancreatic cancer, including an explanation of different types.
New Cancer Stem Cell Pathway Drug May Change Standard of Care
Dr. Tanios Bekii-Saab is testing a new drug that works on pancreatic cancer stem cells to make chemotherapy more effective.
A Newly Identified Biomarker Panel Shows Promise in Earlier Pancreatic Cancer Detection
The first pancreatic cancer blood test may soon be a reality, as a biomarker panel from the lab of Dr. Ken Zaret shows promise in early testing.